The implications of angiogenesis on tumor invasiveness

Angiogenesis

Volumn 2, Issue 1, 1998, Pages 21-23

  Christofori, Gerhard ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002833053     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009094124736     Document Type: Short Survey

References (19)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1, 27-31.
2. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147, 9-15.
3. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3, 1222-1227.
4. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56, 172-181.
5. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55, 3964-3968.
6. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57, 5281-5285.
7. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96, 1815-1822.
8. Soff GA, Sanderowitz J, Gately S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in a athymic mouse model. J Clin Invest 1995; 96, 2593-2600.
9. Rosen EM, Goldberg ID. Scatter factor and angiogenesis. Adv Cancer Res 1995; 67, 257-279.
10. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55, 4575-4580.
11. Larcher F, Robles AI, Duran H, et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996; 56, 5391-5396.
12. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1, 149-153.
13. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2, 689-692.
14. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390, 404-407.
15. Parangi S, O'Reilly MS, Christofori G, et al. Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996; 93, 2002-2007.
16. Inbal B, Cohen O, Plak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390, 180-184.
17. Perl A-K, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E cadherin in the transition from adenoma to carcinoma. Nature 1998; in press.
18. Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LCJM, Collard JG. Inhibition of invasion of epithelial cells by Tiam 1-Rac signaling. Science 1997; 278, 1464-1466.
19. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Racl induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997; 390, 632-636.